Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05677737
Other study ID # nihan25
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 15, 2022
Est. completion date July 15, 2023

Study information

Verified date July 2023
Source Ataturk University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Method: It was conducted in a randomized controlled experimental type. The population of the study consisted of 2426 women over the age of 20 living in a family health center in Erzurum between October 2021 and September 2022. The sample of the study consisted of 252 women with 0.05 margin of error and 95% confidence level, according to the sample size calculation formula used in cases where the universe is known. Within the framework of the exclusion criteria of the study, 52 women were excluded from the study and 200 women were included in the randomization.


Description:

Persons in the experimental group will be trained 6 times with an interval of 2 weeks via an online platform (zoom, etc.). No training will be given to the control group, and the post-test data will be collected by re-administering the two groups with the mid-test created via Google forms and containing the scales immediately after the training, and the "Health Belief Model Scale in Breast Cancer Screening" and "Breast Cancer Screening Beliefs Scale" two months later.


Recruitment information / eligibility

Status Completed
Enrollment 165
Est. completion date July 15, 2023
Est. primary completion date May 28, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: -Being over 18 years old - Being literate, - Computer can be used, - Internet is accessible, - Not getting breast cancer before, Exclusion Criteria: - Having received training on breast cancer before - Having a history of breast cancer in first degree relatives - Those who did not attend all of the online trainings in the experimental group

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Education
Educational program; It will be applied to the individuals in the experimental group for an average of 40 minutes in a time period they are suitable through the online platform prepared for the individuals in the experimental group in a three-month period. The literature will be scanned and appropriate educational materials will be created, and videos will be used to support education. Educational program During the first interview, the individuals in the experimental group will be introduced to the online platform, their entrance will be provided, they will be informed about how to follow the trainings, and sample applications will be made. Six main topics will be covered in the training program and will be completed every two weeks in three months.

Locations

Country Name City State
Turkey Ataturk University Erzurum Yakutiye

Sponsors (1)

Lead Sponsor Collaborator
Ataturk University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Breast Cancer Screening Beliefs Scale Breast Cancer Screening Beliefs Questionnaire: The scale was developed by Kwok et al. (2010) in 2010 to determine women's breast cancer screening beliefs. Turkish adaptation, reliability, and validity of the scale were performed by Türkoglu and Sis Çelik in 2021. The scale has three sub scales including Attitudes towards General Health Checkups, Knowledge and Perceptions about Breast Cancer, and Perceived Barriers to Mammographic Screening. Cronbach's alpha internal coefficients were found to range between 0.76 and 0.87 in the sub-scales of the original scale. The scores to be obtained from the scale range between 0 and 100. Mean scores of 65 and over in the sub-scales indicate that screening beliefs increase positively, knowledge level increases, and barriers to mammography screening decrease. two week
Primary Health Belief Model Scale in Breast Cancer Screening This policy was first established by Champion in 1984 in the Health Belief Model base building. The scale has 8 dimensions: sensitivity, caring, health motivation, BSE barriers, benefits, self-efficacy, mammography benefits and barriers. Necessary components were tested, with the scale's caring and health motivation being revised in 1993, refinement in 1999, and BSE benefits, barriers, and self-efficacy dimensions revised again in 1997 (Champion, 1993; Champion and Scott, 1997; Champion, 1999; Champion, 1984) . Turkish validity and reliability were performed by Gözüm and Aydin in 2004. The scale includes subsections of "sensitivity", "caring", "health motivation", "BSE benefits", "BSE barriers", "BSE self-efficacy". The scale is a Likert-type scale scored from 1 to 5. A score closer to 5 means that caring, health motivation, BSE benefits, BSE barriers and BSE self-efficacy are perceived to be high. Two week
See also
  Status Clinical Trial Phase
Completed NCT03080623 - Ultrasound-based Diagnostic Model for Differentiating Malignant Breast Lesion From Benign Lesion
Completed NCT05527769 - Pain and Functional Recovery After Mastectomy and IBR by Implant: Prepectoral Versus Subpectoral Technique
Completed NCT06376578 - Exercise Interventions for Improving Health in Breast Cancer Survivors N/A
Completed NCT03004534 - A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide Early Phase 1
Recruiting NCT05020574 - Microbiome and Association With Implant Infections Phase 2
Active, not recruiting NCT06277141 - The Vitality Mammography Messaging Study N/A
Completed NCT03270111 - High Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women N/A
Completed NCT03555227 - USG PECS vs LIA for Breast Cancer Surgery N/A
Active, not recruiting NCT03917082 - Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer Phase 2
Recruiting NCT05561842 - Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
Completed NCT04554056 - Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF Phase 2/Phase 3
Active, not recruiting NCT03127995 - Hypofractionated vs Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation About Lymphedema Occurrence N/A
Active, not recruiting NCT02237469 - Prone Breast Radiotherapy Treatment Planning Observational Study
Completed NCT01204125 - Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients Phase 2
Recruiting NCT04565054 - Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC Phase 3
Not yet recruiting NCT06412133 - Conversations in Light and Shadow: Assessing Phototherapy's Impact on Breast Cancer Patients N/A
Recruiting NCT03956641 - Evolution of the Physical Condition in Treated Cancer Patients N/A
Recruiting NCT06087120 - Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer.
Recruiting NCT06058936 - Exercises Using Virtual Reality on Cancer Patients N/A
Completed NCT03470935 - Non-interventional Study Evaluating Gynecological Impact of Diagnosis and Treatment of Breast Cancer in Patients Younger